Additional research demonstrated that FMNL2 enhanced the ubiquitin-mediated proteasome degradation of COMMD10, hence reducing the nuclear translocation of NF-κB subunit p65 and promoting tumor progression. The gene discussed is FMNL2; the disease is neoplasm.